NGM Biopharmaceuticals Inc R&D Event (Virtual) Transcript

Jun 29, 2022 / 03:00PM GMT
Brian Schoelkopf - NGM Biopharmaceuticals, Inc. - Senior Director of Corporate Finance & IR

Good morning, and thank you for joining us today for the fourth and final session of our Explorer series featuring our clinical program for the treatment of geographic atrophy, NGM621. My name is Brian Schoelkopf, Head of Investor Relations at NGM Bio. We will be making forward-looking statements during today's presentation, including statements about anticipated timing of events and the potential benefit of our product candidates. We refer you to our most recent 10-K, which identifies factors that could cause actual results to differ materially from today's forward-looking statements. I encourage you to read the full language on this slide and all of the slides that will be presented today. They will be posted to the Investors and Media section of our website.

And with that, I will hand it over to David Woodhouse, PhD, and Chief Executive Officer at NGM Bio. David?

David J. Woodhouse - NGM Biopharmaceuticals, Inc. - CEO & Director

Thank you, Brian. It's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot